Zeranovia(TM) Weight Loss Product Shows Promising Results in Dosage Trial

Rhea-AI Summary

BioAdaptives Inc. (OTC: BDPT) has announced successful completion of dosage trials for its weight loss product Zeranovia™. The trial demonstrated significant results, with participants experiencing weight loss of 5-7 pounds per week with minimal side effects.

Key findings include consistent weight loss across participants, with the main side effect being mild gastrointestinal discomfort, manageable through increased water intake or dosage adjustments. All trial subjects requested to proceed to the next phase, demonstrating high satisfaction levels.

Based on these promising results, BioAdaptives is proceeding with dosage adjustments for the next stage of clinical trials, aiming to address the global need for effective and safe weight loss solutions.

Positive

• Strong weight loss results: 5-7 pounds per week in trial participants
• High participant satisfaction with all subjects requesting to continue to next phase
• Minimal and manageable side effects reported

Negative

• Product still in early trial phases, requiring additional clinical testing
• Presence of gastrointestinal side effects, though mild

LAS VEGAS, March 13, 2025 (GLOBE NEWSWIRE) -- via IBN -- BioAdaptives Inc. (OTC: BDPT) today announced the successful completion of dosage trials for its innovative weight loss product, Zeranovia™. The trial demonstrated significant weight loss results with minimal side effects, marking a crucial product development milestone.

During the trial, participants experienced weight loss ranging from 5 to 7 pounds per week. Side effects were minimal, with the most common being mild gastrointestinal discomfort, which was easily managed by increasing water intake or adjusting the product dosage.

"We are thrilled with the results of this dosage trial," said James Keener, CEO. "The consistent weight loss across participants, coupled with the manageable side effect profile, indicates that Zeranovia™ has the potential to be a game-changer in the weight loss market."

Key findings from the dosage trial include:

• Consistent weight loss across participants
• Minimal side effects, easily managed with simple adjustments
• High participant satisfaction, with all trial subjects requesting to proceed to the next phase
  

Based on these promising results, BioAdaptives is moving forward with dosage adjustments for the next stage of clinical trials. The company is optimistic about the product's potential to address the growing global need for effective and safe weight loss solutions.

"The enthusiasm from our trial participants is incredibly encouraging," added Keener. "Their eagerness to continue with the next phase of testing speaks volumes about the product's effectiveness and tolerability."

BioAdaptives is committed to developing innovative solutions for weight management. The company anticipates releasing further updates as the clinical trial progresses.

About BioAdaptives, Inc.

BioAdaptives, Inc. (OTC: BDPT) is a leading innovator in the health and wellness industry. We are dedicated to developing and marketing nutraceutical and wellness products that harness the power of natural ingredients and cutting-edge science. Our mission is to improve the quality of life for our customers by offering products that support optimal health and vitality.

For more information, please visit our website at www.bioadaptives.com.

Contact Information:

BioAdaptives, Inc.
Emily Harrison
IR Coordinator
(702)-659-8829
info@bioadaptives.com
2620 Regatta Dr, Suite 102
Las Vegas, NV 89128

Forward-Looking Statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, among other things, statements regarding expected growth, potential benefits of the company's products, and future business opportunities. These statements involve risks, uncertainties, and other factors that may cause actual results or developments to differ materially from those expressed or implied.

Wire Service Contact:

IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
Editor@InvestorBrandNetwork.com

FAQ

What were the weight loss results from BDPTD's Zeranovia trial?

Participants in the Zeranovia dosage trial experienced weight loss ranging from 5 to 7 pounds per week.

What side effects were reported in BioAdaptives' Zeranovia weight loss trial?

The main side effect was mild gastrointestinal discomfort, which could be managed by increasing water intake or adjusting product dosage.

How did participants respond to BDPTD's Zeranovia weight loss product?

All trial participants showed high satisfaction and requested to proceed to the next phase of testing.

What is the next step for BioAdaptives' Zeranovia after the successful dosage trial?

BioAdaptives is moving forward with dosage adjustments for the next stage of clinical trials.